Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards

J&J CEO says getting a COVID-19 vaccine could be an annual ritual for years

By Sean Whooley | February 10, 2021

Johnson & JohnsonJohnson & Johnson (NYSE:JNJ) CEO Alex Gorsky said people may need COVID-19 vaccines annually, like flu shots, over the next several years.

Speaking to CNBC, Gorsky cited the mutations and variants of the disease, several of which have already landed in the U.S., as the driving force behind differentiating capabilities of the vaccine to fight off antibodies. Previous suggestions have indicated that COVID-19 could become a flu-like endemic disease, too.

Johnson & Johnson submitted an application for FDA emergency use authorization (EUA) last week for its one-dose vaccine in the hopes that it could begin distributing it in the U.S. alongside the two previously authorized vaccines from Pfizer/BioNTech and Moderna, both of which require two doses about three to four weeks apart.

The company expects to have its product available to ship immediately following FDA authorization, as well. Johnson & Johnson set its target to produce 1 billion doses in 2021 and expand production after that. The company has committed to not-for-profit pricing during the pandemic assuming its single-dose vaccine is authorized by FDA and other regulators. J&J is also investigating a two-dose regimen for its vaccine.

In August 2020, the U.S. Dept. of Health and Human Services and Defense Dept. agreed to a $1 billion deal for a vaccine candidate from Johnson & Johnson’s Janssen Pharmaceutical subsidiary, meaning authorization in the U.S. would bring a welcome addition to the effort to get the country vaccinated.

Gorsky told CNBC that the company is confident it will meet its target of delivering 100 million doses of the vaccine to the U.S. by the end of June as it works “full speed” on manufacturing with sights set on safely and effectively accelerating production.

Tell Us What You Think! Cancel reply

Related Articles Read More >

Johnson & Johnson Merck COVID-19 vaccine
Biden announces partnership for Merck to make J&J’s COVID-19 vaccine
COVID-19 vaccine
Biden announces $4B to support global vaccinations worldwide
COVID-19 vaccine
Feds order 200M more vaccine doses from Pfizer, Moderna
Merck
Merck KGaA to supply lipids to boost Pfizer-BioNTech COVID-19 vaccine production

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Pharmaceutical Processing news in a minute?

We Deliver!
Pharmaceutical Processing Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Pharmaceutical Processing World
  • Enews Signup
  • Contact Us
  • About Us
  • R&D World
  • DeviceTalks
  • Drug Discovery & Development
  • Drug Delivery Business News
  • MassDevice
  • Medical Design Sourcing

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Enterprise Technology
  • Contract Manufacturing
  • R&D 100 Awards